Encaleret for Hypoparathyroidism
(RECLAIM-HP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
Who Is on the Research Team?
Calcilytix Medical Director
Principal Investigator
Calcilytix Therapeutics, Inc., a BridgeBio company
Are You a Good Fit for This Trial?
This trial is for people with chronic hypoparathyroidism (low parathyroid hormone) for at least 6 months. They must have stable calcium and vitamin D supplements, normal magnesium levels, and be able to stop certain water pills if needed. Genetic testing may be required for some types of the disease.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Encaleret
Trial Overview
The study compares encaleret tablets taken by mouth versus a placebo in people with chronic hypoparathyroidism to see how well encaleret works and how safe it is. Participants are randomly assigned to either group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive encaleret during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label long-term extension (LTE) period to continue receiving encaleret for up to 192 weeks.
Participants will receive placebo during the 24-week double-blind treatment period. Participants will then have the option to enter an open-label LTE period to receive encaleret for up to 192 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Calcilytix Therapeutics, Inc., a BridgeBio company
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.